BRCA1 and breast cancer: Notably, for patients with breast cancer harbouring BRCA1/2 germline mutations, carboplatin proved superior to docetaxel (ORR: 68.0% vs 33.3%, p = 0.03; PFS: 6.8 vs 4.4 months, p = 0.002) (Tutt et al., 2018).